Kainomyx Announces New Funding To Advance Programs Focused On Malaria And Other Parasitic Diseases
10/26/21, 3:41 PM
Location
palo altoKainomyx, Inc., founded in September 2019 and financed with $7.5M in May 2020, announced a new round of funding of $7.97M to advance its programs in malaria therapeutics, malaria diagnostics and therapeutics for other parasitic diseases. Kainomyx was founded by five current and former Stanford scientists who are experts in the biology, biochemistry, and biophysics of the cytoskeletal proteins of cells - James Spudich, PhD, Annamma Spudich, PhD, Darshan Trivedi, PhD, Suman Nag, PhD and Kathleen Ruppel, MD, PhD. Together, they share a conviction that there is a critical need for new therapeutic innovations for treating malaria, leishmaniasis, and other parasitic diseases.
Company Info
Location
palo alto, california, united states
Additional Info
Kainomyx was founded by five current and former Stanford scientists who are experts in the biology, biochemistry, and biophysics of the cytoskeletal proteins of cells - James Spudich, PhD, Annamma Spudich, PhD, Darshan Trivedi, PhD, Suman Nag, PhD and Kathleen Ruppel, MD, PhD. Kainomyx is not only developing novel therapeutic approaches to treat malaria, but also developing sensitive, accurate, easy to execute diagnostic tests to identify asymptomatic carriers who contribute to the transmission of malaria parasites. In addition, Kainomyx received a grant of $1.97M from the Bill & Melinda Gates Foundation to advance Kainomyx’s program in malaria therapeutics.